207 related articles for article (PubMed ID: 30174414)
1. Preparation and characterization of pH-sensitive nanoparticles of budesonide for the treatment of ulcerative colitis.
Zhou H; Qian H
Drug Des Devel Ther; 2018; 12():2601-2609. PubMed ID: 30174414
[TBL] [Abstract][Full Text] [Related]
2. Dual Functional Eudragit
Gao C; Yu S; Zhang X; Dang Y; Han DD; Liu X; Han J; Hui M
Int J Nanomedicine; 2021; 16():1405-1422. PubMed ID: 33658780
[TBL] [Abstract][Full Text] [Related]
3. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases.
Ali H; Weigmann B; Neurath MF; Collnot EM; Windbergs M; Lehr CM
J Control Release; 2014 Jun; 183():167-77. PubMed ID: 24685705
[TBL] [Abstract][Full Text] [Related]
4. Budesonide Loaded PLGA Nanoparticles for Targeting the Inflamed Intestinal Mucosa--Pharmaceutical Characterization and Fluorescence Imaging.
Ali H; Weigmann B; Collnot EM; Khan SA; Windbergs M; Lehr CM
Pharm Res; 2016 May; 33(5):1085-92. PubMed ID: 26718953
[TBL] [Abstract][Full Text] [Related]
5. Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy.
Naeem M; Choi M; Cao J; Lee Y; Ikram M; Yoon S; Lee J; Moon HR; Kim MS; Jung Y; Yoo JW
Drug Des Devel Ther; 2015; 9():3789-99. PubMed ID: 26229440
[TBL] [Abstract][Full Text] [Related]
6. Preparation and in vitro/in vivo evaluation of dextran matrix tablets of budesonide in experimental ulcerative colitis in rats.
Ahmadi F; Varshosaz J; Emami J; Tavakoli N; Minaiyan M; Mahzouni P; Dorkoosh F
Drug Deliv; 2011 Feb; 18(2):122-30. PubMed ID: 20954795
[TBL] [Abstract][Full Text] [Related]
7. Engineering of budesonide-loaded lipid-polymer hybrid nanoparticles using a quality-by-design approach.
Leng D; Thanki K; Fattal E; Foged C; Yang M
Int J Pharm; 2018 Sep; 548(2):740-746. PubMed ID: 28847667
[TBL] [Abstract][Full Text] [Related]
8. Colon-targeted delivery of cyclosporine A using dual-functional Eudragit
Naeem M; Bae J; Oshi MA; Kim MS; Moon HR; Lee BL; Im E; Jung Y; Yoo JW
Int J Nanomedicine; 2018; 13():1225-1240. PubMed ID: 29535519
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis.
Varshosaz J; Emami J; Tavakoli N; Fassihi A; Minaiyan M; Ahmadi F; Dorkoosh F
Int J Pharm; 2009 Jan; 365(1-2):69-76. PubMed ID: 18804521
[TBL] [Abstract][Full Text] [Related]
10. Colitis-targeted hybrid nanoparticles-in-microparticles system for the treatment of ulcerative colitis.
Naeem M; Lee J; Oshi MA; Cao J; Hlaing SP; Im E; Jung Y; Yoo JW
Acta Biomater; 2020 Oct; 116():368-382. PubMed ID: 32937207
[TBL] [Abstract][Full Text] [Related]
11. Garcinol Encapsulated Ph-Sensitive Biodegradable Nanoparticles: A Novel Therapeutic Strategy for the Treatment of Inflammatory Bowel Disease.
Jacob EM; Borah A; Pillai SC; Kumar DS
Polymers (Basel); 2021 Mar; 13(6):. PubMed ID: 33799680
[TBL] [Abstract][Full Text] [Related]
12. pH-triggered surface charge-reversal nanoparticles alleviate experimental murine colitis via selective accumulation in inflamed colon regions.
Naeem M; Oshi MA; Kim J; Lee J; Cao J; Nurhasni H; Im E; Jung Y; Yoo JW
Nanomedicine; 2018 Apr; 14(3):823-834. PubMed ID: 29353017
[TBL] [Abstract][Full Text] [Related]
13. Preparing simvastatin nanoparticles by a combination of pH-sensitive and timed-release approaches for the potential treatment of ulcerative colitis.
Fardafshari F; Taymouri S; Minaiyan M; Tavakoli N
J Biomater Appl; 2022 Nov; 37(5):859-871. PubMed ID: 35999010
[TBL] [Abstract][Full Text] [Related]
14. Optimization of budesonide compression-coated tablets for colonic delivery.
Yehia SA; Elshafeey AH; Sayed I; Shehata AH
AAPS PharmSciTech; 2009; 10(1):147-57. PubMed ID: 19199041
[TBL] [Abstract][Full Text] [Related]
15. Budesonide-Loaded Eudragit S 100 Nanocapsules for the Treatment of Acetic Acid-Induced Colitis in Animal Model.
Qelliny MR; Aly UF; Elgarhy OH; Khaled KA
AAPS PharmSciTech; 2019 Jun; 20(6):237. PubMed ID: 31243601
[TBL] [Abstract][Full Text] [Related]
16. Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease.
Leonard F; Srinivasan S; Liu X; Collnot EM; Ferrari M; Lehr CM; Godin B
Eur J Pharm Biopharm; 2020 Jun; 151():61-72. PubMed ID: 32283213
[TBL] [Abstract][Full Text] [Related]
17. Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations.
Sahib MN; Darwis Y; Peh KK; Abdulameer SA; Tan YT
Int J Nanomedicine; 2011; 6():2351-66. PubMed ID: 22072872
[TBL] [Abstract][Full Text] [Related]
18. Preparation of budesonide-dextran conjugates using glutarate spacer as a colon-targeted drug delivery system: in vitro/in vivo evaluation in induced ulcerative colitis.
Varshosaz J; Emami J; Ahmadi F; Tavakoli N; Minaiyan M; Fassihi A; Mahzouni P; Dorkoosh F
J Drug Target; 2011 Feb; 19(2):140-53. PubMed ID: 20429772
[TBL] [Abstract][Full Text] [Related]
19. Colon specific delivery of budesonide based on triple coated pellets: in vitro/in vivo evaluation.
Varshosaz J; Emami J; Tavakoli N; Minaiyan M; Rahmani N; Dorkoosh F; Mahzouni P
Acta Pharm; 2012 Nov; 62(3):341-56. PubMed ID: 23470347
[TBL] [Abstract][Full Text] [Related]
20. Oral administration of pH-sensitive curcumin-loaded microparticles for ulcerative colitis therapy.
Xiao B; Si X; Zhang M; Merlin D
Colloids Surf B Biointerfaces; 2015 Nov; 135():379-385. PubMed ID: 26275840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
